Sylvie Pilon, VP and GM at Lundbeck Canada, shares the highlights of her first year leading the Canadian affiliate; the challenges associated with Canada’s complex market access environment, particularly for mental illnesses; Lundbeck’s commitment to supporting patient associations in order to reduce the stigma associated with mental health conditions; and her priorities for the next few years.
Sylvie, coming up to the first-year anniversary of your appointment as VP and GM of Lundbeck Canada, what have been some key milestones or achievements?
"Canada has traditionally been a very important market for Lundbeck but recent changes to the market access system in terms of both Health Technology Assessment (HTA) and pricing and reimbursement are proving to be challenging."
